
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| renal cell carcinoma | EFO_0000376 | D002292 | — |
Expiration | Code | ||
|---|---|---|---|
CABOZANTINIB S-MALATE, CABOMETYX, EXELIXIS INC | |||
| 2028-09-17 | ODE-375 | ||
| 2026-01-14 | ODE-227 | ||
| 2024-09-17 | I-873 | ||
| 2024-01-22 | I-854 | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cabozantinib S-Malate, Cabometyx, Exelixis Inc | |||
| 9724342 | 2033-07-09 | DP | |
| 11298349 | 2032-02-10 | DP | |
| 10034873 | 2031-07-18 | U-2488 | |
| 10039757 | 2031-07-18 | U-1480 | |
| 8877776 | 2030-10-08 | DS, DP | U-1617, U-3225 |
| 11091439 | 2030-01-15 | DP | |
| 11091440 | 2030-01-15 | DP | |
| 11098015 | 2030-01-15 | U-1220, U-1480, U-1617, U-2488, U-3225 | |
| 7579473 | 2026-08-14 | DS, DP | |
| 8497284 | 2024-09-24 | U-1220, U-1480, U-2488 | |
| Cabozantinib S-Malate, Cometriq, Exelixis | |||
| 9717720 | 2032-02-10 | DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 2 | — | 1 | 13 | 16 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | 1 | — | — | 2 |
| Papillary thyroid cancer | D000077273 | — | — | — | — | 1 | — | — | 1 |
| Follicular adenocarcinoma | D018263 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 3 | — | — | 9 | 12 |
| Neoplasms | D009369 | — | C80 | — | 6 | — | — | — | 6 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 2 | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 2 | — | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 2 | — | — | — | 2 |
| Osteosarcoma | D012516 | — | — | — | 2 | — | — | — | 2 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Anaplastic thyroid carcinoma | D065646 | — | — | — | 1 | — | — | — | 1 |
| Paraganglioma | D010235 | — | — | — | 1 | — | — | — | 1 |
| Drug common name | Cabozantinib |
| INN | cabozantinib |
| Description | Cabozantinib is a dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer. It has a role as a tyrosine kinase inhibitor and an antineoplastic agent. It is a member of quinolines, an organofluorine compound, an aromatic ether and a dicarboxylic acid diamide. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC |
| PDB | — |
| CAS-ID | 849217-68-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105717 |
| ChEBI ID | 72317 |
| PubChem CID | 25102847 |
| DrugBank | DB08875 |
| UNII ID | 1C39JW444G (ChemIDplus, GSRS) |

